TABLE 4.
The studies on materials reducing endophthalmitis.
| Drug | Surface modification | IOL optic materials | Technique | Article |
|---|---|---|---|---|
| MXF* | AMPS*/SBMA* | Hydrophilic acrylic | Plasma grafting | Pimenta et al. (2017) |
| PHEMA coating | Hydrophilic acrylic | Argon plasma-assisted grafting | Vieira et al. (2017) | |
| AMP* | PSS*-PEI | PMMA | LBL assembly | Manju and Kunnatheeri, (2010) |
| Vancomycin | Poly 2/polyanion/vancomycin/polyanion | LBL assembly | Shukla et al. (2011) | |
| NFX* | Octadecyl isocyanate | Hydrophilic acrylic | Grafting | Anderson et al. (2009) |
| Gentamycin | PPPE* IOL-PDA | Hydrophobic acrylic | Yang et al. (2021) | |
| No antibiotics | p (DMAEMA*-CO-MPC) brush | Silicon | SI-RAFT | Wang et al. (2017) |
| p (VBC-CO-DMAEMA) | Chemical vapor deposition | Choi et al. (2020) | ||
| HA*-CHI* | Silicon | Polyelectrolyte deposition | Lin et al. (2017a) |
*MXF, moxifloxacin; AMP, ampicillin; NFX, norfloxacin; AMPS, 2-acrylamido-2-methylpropane sulfonic acid; SBMA, (2-(methacryloyloxy)ethyl) dimethyl-(3-sulfopropyl) ammonium hydroxide; PSS, poly (sodium 4-styrenesulfonate); PPPE, poly (2-phenoxyethyl methacrylate-co-2-phenoxyethyl acrylate-co-2-ethylhexyl methacrylate); DMAEMA, 2-(dimethylamino)-ethyl methacrylate; HA, hyaluronic acid; CHI, chitosan polyelectrolyte.